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What is already known about this topic? Asthma is now understood to encompass a variety of distinct clinical phe-
notypes, likely arising from different pathological mechanisms.
What does this article add to our knowledge? In a large international severe asthma cohort, distinct clusters according
to biomarker expression exhibited unique clinical characteristics, suggesting the occurrence of discrete patterns of un-
derlying inflammatory pathway activation.
How does this study impact current management guidelines? Understanding more about distinct patterns of un-
derlying inflammatory pathway activation in individual severe asthma patients allows clinicians to tailor targeted severe
asthma therapies such as monoclonal biologics, furthering precision medicine for severe asthma.llergy, Asthma, and Clinical Immunology, Alfred Health, Melbourne, Australia
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eva; islood eosinophil count
BMI- Body mass indexFeNO- Fractional exhaled nitric oxide
FEV1- Forced expiratory volume in one second
GINA- Global Initiative for Asthma
IgE- Immunoglobulin EISAR- International Severe Asthma RegistryBACKGROUND: Allergy, eosinophilic inflammation, and
epithelial dysregulation are implicated in severe asthma
pathogenesis.
OBJECTIVE: We characterized biomarker expression in adults
with severe asthma.
METHODS: Within the International Severe Asthma Registry
(ISAR), we analyzed data from 10 countries in North America,
Europe, and Asia, with prespecified thresholds for biomarker
positivity (serum IgE ‡ 75 kU/L, blood eosinophils ‡ 300 cells/
mL, and FeNO ‡ 25 ppb), and with hierarchical cluster analysis
using biomarkers as continuous variables.
RESULTS: Of 1,175 patients; 64% were female, age (mean –
SD) 53 – 15 years, body mass index (BMI) 30 – 8,
postbronchodilator forced expiratory volume in 1 second (FEV1)
predicted 72% – 20%. By prespecified thresholds, 59% were IgE
positive, 57% eosinophil positive, and 58% FeNO positive.
There was substantial inflammatory biomarker overlap; 59%
were positive for either 2 or 3 biomarkers. Five distinct clusters
were identified: cluster 1 (61%, low-to-medium biomarkers)
comprised highly symptomatic, older females with elevated BMI
and frequent exacerbations; cluster 2 (18%, elevated eosinophils
and FeNO) older females with lower BMI and frequent exacer-
bations; cluster 3 (14%, extremely high FeNO) older, highly
symptomatic, lower BMI, and preserved lung function; cluster 4
(6%, extremely high IgE) younger, long duration of asthma,
elevated BMI, and poor lung function; cluster 5 (1.2%,
extremely high eosinophils) younger males with low BMI, poor
lung function, and high burden of sinonasal disease and
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One in 10 patients with asthma suffers from severe asthma,
which often remains uncontrolled despite treatment with high-
dose inhaled corticosteroids plus a second controller.1 These
individuals account for the most health care expenditure, expe-
rience the greatest morbidity, and face the highest risk of death
compared with patients with nonsevere asthma.2-5
A variety of cellular pathways are activated in patients with
severe asthma. Allergy, eosinophilic inflammation, and airway
epithelial dysregulation have each been implicated in the path-
ogenesis of severe asthma.6-10 Accordingly, increased serum
immunoglobulin E (IgE), peripheral blood eosinophils, and
fractional exhaled nitric oxide (FeNO) have been used as bio-
markers to suggest corresponding activation of these respective
inflammatory pathways and to predict responsiveness to mono-
clonal biologics such as those targeting IgE, interleukin-5, and
the interleukin-4/-13 receptor.1,7,9,11-15
It appears likely that different inflammatory pathways in se-
vere asthma may be activated to a different extent in different
patients. We hypothesized that such differential activation of
inflammatory pathways would lead to differential biomarker
expression and would also be manifested by different clinical
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TABLE I. Definition of uncontrolled asthma, participants with at least 1 of the following criteria present
Criteria Definition
Poor symptom control Asthma Control Questionnaire > 1.5, OR Asthma Control Test < 20, OR having 3 or more of
the following during the past 4 weeks (National Asthma Education and Prevention Program
[NAEPP]/GINA guidelines)20,21: daytime symptoms more than twice/wk, night waking due
to asthma, reliever needed more than twice/wk, activity limitation due to asthma.
Evidence of airflow limitation FEV1 < 80% predicted, in the face of reduced FEV1/FVC following a withhold of short- and
long-acting bronchodilators (ie, prebronchodilator)
Evidence of serious exacerbations At least 1 hospitalization, ICU stay, or mechanical ventilation for asthma in the previous year
Evidence of frequent severe asthma exacerbations Two or more asthma exacerbations defined as per the American Thoracic Society/European
Respiratory Society criteria of increased asthma symptoms (cough, shortness of breath,
wheeze) necessitating systemic corticosteroids (or an increase in baseline corticosteroids)
for three or more days or a hospitalization or emergency department visit due to asthma
requiring systemic steroids
FEV1, Forced expiratory volume in one second; FVC, forced vital capacity; ICU, intensive care unit.
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2682 DENTON ETALPrevious studies in a general asthma population have indicated
substantial overlap in inflammatory biomarkers, but this has not
been previously examined in severe asthma patients.18 We tested
this hypothesis using a large cohort of patients with severe asthma,
drawn from the International Severe Asthma Registry (ISAR;
http://isaregistries.org/).19 We aimed to describe the interrelation
between inflammatory biomarkers expression in severe asthma in
order to characterize the activation of underlying inflammatory
pathways. We employed 2 approaches to distinguish patient
groups with different patterns of biomarker activation; first, using
prespecified thresholds for each biomarker, and second, using
cluster analysis. We then compared the clinical characteristics of
the patient subgroups derived from these analyses.METHODS
The study was designed, implemented, and reported in compli-
ance with the European Network Centres for Pharmacoepidemiol-
ogy and Pharmacovigilance (ENCePP) Code of Conduct
(EUPAS30430) and with all applicable local and international laws
and regulation. Governance was provided by the Anonymous Data
Ethics Protocols and Transparency (ADEPT) committee (registra-
tion number ADEPT1019). All data collection sites in ISAR have
obtained regulatory agreement in compliance with specific data
transfer laws, country-specific legislation, and relevant ethical boards
and organizations.
This cross-sectional study included adults with severe asthma
enrolled in ISAR with serum IgE, blood eosinophil count (BEC),
and FeNO available at registry enrollment. The ISAR requests that
the enrollment biomarker measurements be baseline measurements
for patients who have multiple measurements available; for those
with multiple baseline measurements, the highest measurement was
used. At the time of this analysis (July 2019), this multicountry data
repository included data from the baseline visits of patients with
severe asthma from 10 countries, including the United States, the
United Kingdom, Canada, Greece, Italy, Ireland, South Korea,
Bulgaria, Kuwait, and Spain. Patients with severe asthma enrolled in
ISAR are aged 18 years or older and have either uncontrolled asthma
at Global Initiative for Asthma (GINA) step 4 treatment or are
receiving GINA step 5 treatment; all were on high-dose inhaled
corticosteroids. Uncontrolled asthma was defined as at least 1 of the
criteria outlined in Table I.
The biomarkers examined were total serum IgE (kU/L), BEC
(cells/mL), and FeNO (ppb) at the point of enrollment in ISAR. Forthe dichotomous analysis, biomarker positivity was predefined as
total IgE of 75 kU/L or greater,15 BECs of 300 cells/mL or greater,
and FeNO of 25 ppb or greater.22 Patients were classified categor-
ically according to ISAR enrollment biomarker status. Owing to lack
of international consensus on biomarker thresholds, sensitivity an-
alyses were performed for prespecified alternate biomarker thresholds
(IgE  30,  100,  300,  400, and  700; BEC  150 and
 400; and FeNO  50), and allergic sensitization rather than IgE
(defined by positive skin prick testing [wheal > 3 mm] or serum
specific IgE of 0.1 kU/L or greater to at least 1 perennial allergen).
The distribution of each biomarker, overlap of biomarkers, and
combinations of positive biomarkers was described.
Prespecified biomarker combinations
The 8 possible biomarker combinations were described (positive:
IgE, BEC, FeNO, IgE and BEC, IgE and FeNO, BEC and FeNO,
all 3, or none positive). For each, the characteristics at enrollment,
including demographics, lung function, asthma symptoms, exacer-
bations, presence of comorbidities, and asthma medications, were
described. Exacerbations were defined according to American
Thoracic Society/European Respiratory Society criteria.1,23 Exacer-
bations were recorded over the 12-month period prior to enrollment
in the ISAR. Asthma control was determined by standardized and
validated asthma control questionnaires, Asthma Control Test,24
Asthma Control Questionnaire,25 or GINA guidelines.20,21
Comorbidities were defined by a clinician diagnosis after relevant
diagnostic testing and review of medical records and recorded as
current, past, or never. Comorbidities examined were allergic
rhinitis, chronic rhinosinusitis, eczema, and nasal polyps.
Comparison between groups was performed with Pearson chi-
squared test or one-way analysis of variance with the post hoc
Tuckey test. A P value less than .05 was considered significant.
Adjustment for multiple comparisons was not performed.
A post hoc analysis was performed describing characteristics of the
biomarker groups who were on biologic medications.
Cluster analysis
The distributions of IgE, BEC, and FeNO were examined using
histograms and standardized for analysis using z scores. A pre-
specified primary cluster analysis was then performed with the bio-
markers as continuous variables via Ward minimum variance
hierarchical cluster analysis method with an agglomerative approach
and Ward linkage. A dendrogram was generated to estimate the
number of clusters within the study population. K means cluster





















12% (141) P value
Sex
% female (n)
64 (752) 57† (181) 67 (109) 57 (55) 62 (73) 68 (64) 73 (59) 64 (106) 74† (104) .01
BMI mean (SD) 30 (7.5) 29† (0.02) (6.5) 29† (0.04) (6.7) 31 (8.9) 30 (7) 32 (7.5) 30 (6.3) 32†z (9.3) 31 (7.6) .004




51 (15) 57z (15) 51† (15) 55k (15) <.001
Asthma control{: poor % of group (n) 80 (510) 73 (131) 84 (81) 77 (43) 75 (52) 78 (39) 84 (37) 91 (71) 85 (56) .2
Exacerbations mean (SD) 4 (4) 4 (4) 3.9 (4) 4.8 (4) 4.4 (4) 4 (4) 4.5 (4) 3.7 (4) 3.3 (3) NS (.6)
FEV1 pre %predicted mean (SD) 72 (22) n ¼ 1,095 71 (22) 74 (21) 67 (25) 73 (22) 71 (20) 69 (18) 69 (21) 75 (22) NS (.07)
Allergic rhinitis: current % group (n) 60 (488) 62 (129) 61 (64) 62 (39) 62 (42) 66 (50) 60 (32) 52 (69) 60 (63) NS (n ¼ 812)
Chronic rhinosinusitis: current % group (n) 66 (354) 66 (92) 62 (48) 68 (27) 73 (37) 62 (31) 80 (31) 65 (46) 65 (42) NS (n ¼ 533)
Eczema: current % group (n) 10 (104) 7 (20) 9 (14) 12 (10) 10 (11) 7 (6) 11 (8) 12 (19) 13 (16) NS (n ¼ 1,069)
Nasal polyps: current % group (n) 35 (204) 42 (74) 40 (40) 31 (14) 30 (20) 37 (15) 30 (12) 27 (13) 28 (16) NS (n ¼ 577)
Chronic oral corticosteroid use % (n) 46 (541) 44 (138) 50 (81) 51 (49) 42 (49) 50 (47) 52 (42) 44 (72) 45 (63)
Anti-IgE % (n) 17 (194) 23 (72) 9 (14) 29 (28) 21 (25) 3 (3) 5 (4) 24 (40) 6 (8)
Anti-IL-5 % (n) 29 (338) 33 (104) 28 (45) 27 (26) 31 (37) 27 (25) 40 (32) 23 (38) 22 (31)
Eos, blood eosinophils; IL-5, interleukin 5; NS, not significant.
*Using predefined cutoffs of blood eosinophils  300 cells/mL, FeNO  25 ppb, total IgE  75 kU/L.
†,z,x,kDenote significant between group differences.
{Definition of poor asthma control: Asthma Control Questionnaire > 1.5, OR Asthma Control Test < 20, OR having three or more of the following during the past 4 weeks (National Asthma Education and Prevention Program [NAEPP]/










































FIGURE 1. Overlap of baseline positivity of 3 clinically used bio-
markers, blood eosinophils  300 cells/mL, FeNO  25 ppb, total
IgE  75 kU/L, in the ISAR severe asthma cohort.
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different cluster numbers. Detailed cluster analysis methods are
available in the Online Repository Text, Section 1, including Figure
E1 and Table E1 (available in this article’s Online Repository at
www.jaci-inpractice.org). Comparisons between clusters were per-
formed with Pearson chi-squared test for categorical variables (pre-
sented as % of total) and one-way analysis of variance for continuous
variables (presented as mean  SD).
RESULTS
Total cohort
Of 6,270 adults with severe asthma, 1,175 with available
biomarkers were included in the study. Characteristics at
enrollment are described in Table II. The majority of patients
were from the United States (49%) and the United Kingdom
(31%). Patients were predominantly white (81%) and female
(64%), with a mean age of 53 years and mean body mass index
(BMI) of 30 kg/m2.
The majority of patients (80%) had uncontrolled asthma
symptoms, and experienced a mean of 4 asthma exacerbations in
the 12 months prior to enrollment. Mean prebronchodilator
forced expiratory volume in 1 second (FEV1) was 72% predicted,
prebronchodilator forced vital capacity (FVC) of 88% predicted,
and FEV1/FVC 69%.
Patient subgroups according to prespecified
biomarker thresholds
Overall, using predetermined biomarker thresholds, 57% were
BEC positive, 58% FeNO positive, and 59% IgE positive, with
substantial overlap (Figure 1). The likelihood that 1 biomarker
was positive when another was positive is presented in Figure 2.Classification according to positivity or negativity to each
biomarker yielded 8 patient subgroups; triple biomarker positive
(27% of the total cohort), BEC and FeNO positive (14%), BEC
and IgE positive (8%), FeNO and IgE positive (10%), only BEC
positive (8%), only FeNO positive (7%), only IgE positive
(14%), and triple biomarker negative (12%).
Demographic and clinical characteristics
Characteristics of each biomarker group are shown in Table II.
There were significantly more females among triple negative
biomarker patients (74%) than among triple biomarker positive
patients (57%; P ¼ .01). The BMI was lower in triple biomarker
positive and BEC/FeNO positive patients than in those patients
who were only IgE positive. Patients with BEC/FeNO positivity,
FeNO positivity, and triple biomarker negativity were signifi-
cantly older than patients who were FeNO/IgE positive and IgE
positive only. There were no significant between-group
differences for asthma symptoms, exacerbations, or FEV1 %
predicted.
Despite changing the biomarker thresholds for the sensitivity
analyses, there was still considerable biomarker overlap between
groups, although the characteristics of the groups did change.
These results are presented in the Online Repository Text,
Section 2, Tables E2-E5. A post hoc analysis was performed
describing those in each biomarker group on biologic medica-
tions and those who had known information on biomarkers
being measured prior to biologic medication initiation; these
results are presented in Table E5 and Figure E2 (available in this
article’s Online Repository at www.jaci-inpractice.org).
In 1 sensitivity analysis, replacing total IgE with allergic
sensitization as a more relevant marker of atopy, the largest
patient group was triple biomarker positive (34%), whereas
only 5% were triple negative. In this analysis, the triple
biomarker negative group also had the highest BMI (35 vs 30
in the whole group). No significant difference was found in age,
sex, or lung function between groups in this analysis, although
there was a trend toward more uncontrolled disease and less
allergic rhinitis and chronic sinusitis in the triple biomarker
negative group.
Cluster analysis
Histograms showed a large range of distributions for all 3
biomarkers (serum IgE, BEC, and FeNO). Extreme outliers were
excluded from the IgE and BEC groups. Biomarker values were
then standardized using z scores for inclusion in the cluster
analysis.
The dendrogram used for estimation of the number of clus-
ters within the studied population is shown in the Online Re-
pository Text, Figure E1, A (available in this article’s Online
Repository at www.jaci-inpractice.org). K means cluster analysis
was performed with the 5 distinctive clusters identified via the
hierarchical cluster approach and also repeated with 4 and 6
clusters to assess the stability of clusters. The consistency of the 2
different cluster analysis methods was high, with similar patient
numbers in each cluster using the 2 methods. The stability of
smaller clusters was also found to be high when using different
numbers of clusters.
Final results identified 5 clusters within the severe asthma
cohort (Figure 3, Table III, and Figure E1, B) (available in this
article's Online Repository at www.jaci-inpractice.org); a sum-
mary is presented later with mean biomarker values for each
FIGURE 2. Percent likelihood that other biomarkers are positive based on positivity of another biomarker in the ISAR.
FIGURE 3. Graphical representation of the clinical characteristics of the 5 severe asthma clusters relating to 3 biomarker levels identified
on hierarchical cluster analysis performed with blood eosinophils, total IgE, and FeNO.
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cluster are shown in Figure 4 and Table III. There was stability of
clusters when repeating cluster analysis with greater and fewer
numbers of clusters and different cluster techniques.
Cluster 1: Older, symptomatic, obese females
(61%). The biomarker profile in this group showed relatively
low mean serum IgE (167 kU/L), BEC (40 cells/mL), and FeNO
(23 ppb), although many patients in this group would still have
positive biomarkers based on traditional prespecified biomarker
thresholds. Clinically, this large cluster was composed predomi-
nantly of older, obese females who had poor asthma control and
frequent exacerbations. Lung function was mildly impaired with
a mean FEV1 % predicted of 71%.Cluster 2: Older, eosinophilic, exacerbating females
(18%). The biomarker profile showed high mean BEC (911
cells/mL), elevated FeNO (51 bpp), and relatively low IgE (187
kU/L). Clinically, this large cluster comprised mainly older fe-
males with lower BMI, with a relatively shorter duration of
asthma. Despite preserved lung function and fewer patients with
poor symptom control, this cluster had the highest number of
exacerbations of any cluster.
Cluster 3: Older, symptomatic, high FeNO,
preserved lung function (14%). The biomarker profile
was characterized by very high FeNO (166 ppb), and moderately
elevated IgE (358 kU/L) and BEC (509 cells/mL). Clinically, this
cluster comprised the oldest patients with a significantly lower
TABLE III. Characteristics of 5 clusters identified via hierarchical cluster analysis
Characteristic Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Total P value*
Number 669 (61%) 200 (18%) 149 (14%) 66 (6%) 13 (1.2%) 1,097
Female sex 66%* 67%* 58% 53% 39%* 64% .01
Age 53  15 54  14 56  15† 49  18† 51  15 53  15 .03
BMI 31  8†z 28  6z 28  6† 31  8 27  6 30  8 <.001
FEV1 % predicted 71  21 73  23 75  23 69  18 68  18 72  22 NS
Blood eosinophils 240  174 911  372 509  310 333  225 4,475  1,755 452  581 <.001
IgE 167  202 187  234 358  402 1,932  1,181 698  824 318  584 <.001
FeNO 23  17 51  23 166  140 38  29 54  44 46  48 <.001
Allergic sensitization 78% 84% 72% 81% 60% 78% NS
Asthma duration 26  17 25  17 26  18 33  17 28  17 26  17 NS
Asthma exacerbations 4.1  3.9 4.5  4.7 3.6  3.2 3.7  3.3 3.4  2 4.1  3.9 NS
Asthma control 84% 72% 80% 68% 71% 79% .003
Allergic rhinitis (current) 58% 63% 62% 65% 82% 60% NS
Chronic rhinosinusitis (current) 66% 70% 62% 64% 75% 67% NS
Nasal polyps (current) 30% 44% 34% 44% 71% 36% .01
Eczema (current) 11% 8% 7% 12% 15% 10% NS
Baseline oral corticosteroids 47% 48% 45% 38% 39% 46% NS
NS, not significant.
Bold indicates statistical significance (P < .05).
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FIGURE 4. Clinical characteristics of the 5 severe asthma clusters relating to 3 biomarker levels identified on hierarchical cluster analysis
performed with blood eosinophils, total IgE and FeNO. Clusters 1 to 5 along the x axis.
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function. Despite a relatively low number of exacerbations,
asthma symptom control remained poor.Cluster 4: Younger, high IgE, obese, poor lung
function (6%). The biomarker profile showed very high IgE
(1932 kU/L), with moderately elevated BEC (333 cells/mL) and
FeNO (38 ppb). Clinically, this cluster comprised the youngest
patients (mean age 49 years) with the most even gender balance and
the longest duration of asthma of any cluster. TheBMIwas high and
lung function was low, yet this cluster had relatively fewexacerbations, the best symptom control, and the fewest patients on
maintenance oral corticosteroids.
Cluster 5: Younger males, eosinophilic, low BMI and
lung function with nasal polyps (1.2%). The
biomarker profile was characterized by extremely high BEC
(4,475 cells/mL), with elevation of FeNO (54 ppb) and IgE
(698 kU/L)
This was a very small cluster (but highly conserved across
different cluster analysis methods and with analysis using different
cluster numbers). Clinically, the cluster comprised younger males,
with the lowest BMI and the lowest lung function, but the least
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symptom control or on chronic oral corticosteroids. This cluster
had a very high prevalence of allergic rhinitis (82%), chronic
rhinosinusitis (75%), and nasal polyps (71%).DISCUSSION
In this large severe asthma cohort, analysis of biomarker
expression by prespecified threshold analysis and cluster analysis
both demonstrated substantial disease heterogeneity, consistent
with previous similar findings in a general asthmatic population.19
According to prespecified thresholds, there was substantial overlap
in biomarker positivity. Cluster analysis of biomarker expression
identified 5 distinct patient clusters. The discrete clustering—
highly conserved between cluster analysis methods—suggests that
differential inflammatory pathway activation in severe asthma
occurs in very specific patterns. Furthermore, each biomarker-
derived cluster was also distinguished by distinct clinical charac-
teristics. Taken together, these findings provide new insights into
the complexity of severe asthma pathogenesis and response to
treatment and have potential relevance for assisting in delivering
precision medicine in the era of targeted monoclonal biologics.
By prespecified biomarker thresholds, almost 60% of patients
were positive for each individual biomarker. These positivity rates
exceeded those reported in a general asthma population, where
36% of participants had elevated eosinophils (300 cells/mL),
18% had high FeNO (35 ppb), and 26% had low FeNO and
blood eosinophils. This finding may indicate that greater inflam-
matory pathway activation occurs in severe asthma patients.26
In addition, 59% were positive for either 2 or 3 biomarkers. The
FeNO and blood eosinophil positivity were more likely to occur
together than with IgE positivity, even though previous studies have
shown that FeNO does not correlate well with blood eosino-
phils.7,9,11 These data mirror findings in a general asthma popula-
tion, inwhich considerable overlap in inflammatory biomarkers also
occurred.18 However, the implication in severe asthma is that such
patients positive for multiple biomarkers may be suitable for mul-
tiple biologic therapies. For this group, new methods are needed to
determine the most appropriate choice of targeted therapy.
Our primary and sensitivity analyses also identified a patient
group whose clinical needs remain unmet by currently available
biologics. This triple biomarker negative group had significantly
more females than the triple biomarker positive group (74% vs
57%), but there were otherwise no significant between-group
differences in smoking status, asthma control, exacerbations,
lung function, or comorbidities.
Cluster analysis has previously been performed in severe asthma
cohorts,12,27-29 but to our knowledge, this is the largest analysis to
date and the first to focus primarily on biomarkers. The discrete
clustering according to biomarker expression that we observed im-
plies that specific combinations of inflammatory pathway activation
predominate in severe asthma, rather than occurring as an even
continuumacross all possible combinations.This supports the notion
that distinct inflammatory endotypes underpin clinically recogniz-
able severe asthma phenotypes. This characterization of biomarker-
derived clusters now identifies new patient subpopulations as a ba-
sis to study relevant disease mechanisms in more detail.
Cluster 1 (older, highly symptomatic obese females with
relatively low biomarkers) probably equates to the obese non-
eosinophilic cluster described by Halder and colleagues27 and the
obese severe asthma cluster identified by Moore and colleagues,28although biomarker status was not fully described in those pa-
tients. Importantly, even though biomarker expression in this
cluster was relatively low, many of these patients would be
suitable for targeted therapies in countries with conventional
biomarker thresholds for biologic eligibility. However, this
cluster is likely to include the majority of the 12% of patients
that were identified as triple negative in the dichotomous anal-
ysis, an important group for targeting future research.
Cluster 2 (significantly elevated BEC and FeNO, older fe-
males with average BMI) and cluster 5 (extremely high BEC,
younger males with sinonasal disease especially nasal polyposis)
have not been previously distinguished in earlier reports of late-
onset eosinophilic asthma. Specifically, cluster 2 did not conform
to previously reported characteristics of worse lung function and
chronic rhinosinusitis and may represent a novel finding.6
Cluster 5 also had unique features including a low BMI and,
given its small size, may include patients with asthma-plus syn-
dromes or hypereosinophilic disorders.
Cluster 3 (very high FeNO, older, slight female predominance,
preserved lung function, and lower BMI) had a larger proportion
with poor symptom control but relatively less frequent exacerba-
tions. This appears to be another novel cluster. Cluster 4 (very
high IgE, equal gender balance, longest duration of asthma, low
lung function, high BMI) probably represents the well-recognized
clinical phenotype of atopic childhood-onset asthma.27 More than
80% of this group had allergic sensitization. The prevalence of
eczema was similar between groups (Table III) so it is unlikely to
be responsible for the IgE elevation. Data on fungal sensitization
were not universally available, so this raises a potential explanation
for extremely high IgE in some patients. The low lung function
may be explained by the long asthma duration and repeated ex-
acerbations or impaired lung growth during childhood and
adolescence. The high BMI may be as a result of chronic oral
corticosteroid exposure or symptoms limiting exercise tolerance.
The ISAR is the largest international registry of severe asthma
patients, with high-quality, patient-level, real-world, standardized
data collected from countries across the world. The heterogeneous
nature of the data is broader than that collected in randomized
controlled trials, and ISAR has the ability to follow patients longi-
tudinally. However, this study has the inherent limitations of an
observational disease registry. Of more than 6,000 patients enrolled
in ISAR, only 1,175 had all 3 biomarkers available at baseline,
introducing the possibility of selection bias. Although prespecified,
the biomarker thresholds were arbitrary, and sensitivity analyses
showed that applying different threshold changed the characteristics
of the groups thus derived (Online Repository Text, Section 2).
Biomarkers were only reported at baseline, so cluster stability in this
cohort remains unclear. Previous data do demonstrate the occur-
rence of biomarker variability over time, and the potential effects of
medications including oral corticosteroids and monoclonal bi-
ologics do limit the interpretation of this study. However, as a real-
world dataset with patients presenting for evaluation having already
been commenced on medications, these data offer pragmatic in-
sights into inflammatory biomarker patterns. The ISAR requests
that the biomarker values be taken prior to initiation of biologic
medications; however, data on baseline medications were limited in
this registry, and although wherever possible the baseline biomarker
measurement was prior to initiating biologic medications, this may
not have been the case in all patients. Of a sample of 281 subjects
who had dates available for both biologic initiation and biomarker
measurement, 240 of these (84%) had their biomarkers measured
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corticosteroids at the time of BEC measurement which may have
affected the measured BEC level, however a repeat analysis
excluding those on oral corticosteroids and biologic medications
showed a similar biomarker overlap to the overall cohort (Online
Repository Text, Section 3, Figure E2).
To conclude, this study has shown considerable overlap of
inflammatory biomarkers in severe asthma, suggesting that a
more comprehensive approach—rather than relying on simple
biomarker threshold positivity—is needed to identify the best
therapy for patients. We have also identified and described 5
severe asthma clusters defined according to biomarker expression.
These data suggest the occurrence of discrete patterns of un-
derlying inflammatory pathway activation and may assist in
providing pathogenic insights relevant to the era of monoclonal
biologics and personalized medicine.
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SECTION 1: CLUSTER ANALYSIS DETAILED
METHODS
Statistical package
SPSS version 24 (IBM, United States) and Microsoft Excel
were used for the cluster analysis and associated analyses.
Cluster analysis methods
The primary cluster analysis methodology was performed us-
ing Ward’s minimum variance hierarchical cluster analysis
method with an agglomerative approach and Ward’s linkage.
This was used to generate a dendrogram for estimation of the
number of clusters within the studied population (Figure E1, A).
K means cluster analysis was used to test the consistency of













31 (367) 17 (195) 13 (150) 6
Eos  400
% (n)
22 (259) 11 (130) 5 (58) 15
FeNO  50
% (n)
18 (209) 8 (93) 17 (204) 5
IgE  30
% (n)
35 (405) 6 (75) 11 (127) 13
IgE  100
% (n)
25 (289) 16 (191) 7 (77) 8
IgE  300
% (n)
14 (163) 27 (317) 3 (36) 5
IgE  400
% (n)
11 (124) 30 (356) 3 (29) 4
IgE  700
% (n)
6 (68) 35 (412) 1 (14) 2
Allergic sensitization
% (n)
34 (276) 10 (81) 13 (107) 16
Baseline oral corticosteroids
% (n)
26 (138) 15 (81) 9 (49) 9
Eos, blood eosinophils; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E.identified via the dendrogram (5) and also 1 less and more than
this to assess the stability of clusters. Using this method the
stability of clusters was found to be high with similar patient
numbers in each cluster using the 2 methods.Selection of variables for analysis
Because this study focused on 3 clinically used
biomarkers—immunoglobulin E, blood eosinophils, and
fractional exhaled nitric oxide—it was prespecified that these 3
continuous variables would be used as the basis for deter-
mining clusters in this population. The distribution of these 3
variables was examined using histograms with all 3 biomarkers
showing a large range of distributions. Extreme outliers were
excluded from the immunoglobulin E and blood eosinophil
groups. The 3 biomarkers were then standardized using
Z-scores.NOD
gED EosD FeNOD IgED NoneD Total
(68) 14 (163) 4 (49) 9 (111) 6 (72) 1,175
(176) 6 (65) 10 (114) 17 (203) 15 (170) 1,175
(64) 14 (164) 3 (30) 19 (219) 16 (192) 1,175
(147) 5 (63) 4 (52) 19 (223) 7 (83) 1,175
(99) 10 (113) 9 (100) 13 (151) 13 (155) 1,175
(56) 13 (154) 12 (143) 7 (84) 19 (222) 1,175
(51) 14 (161) 13 (148) 6 (70) 20 (236) 1,175
(28) 15 (176) 15 (171) 2 (27) 24 (279) 1,175
(130) 2 (17) 6 (49) 14 (109) 5 (39) 808
(49) 9 (47) 8 (42) 13 (72) 12 (63) 541
FIGURE E1. (A) Dendrogram to estimate the number of clusters in
the studied population based on biomarkers total IgE, blood
eosinophil count and fractional exhaled nitric oxide. (B) Clusters
identified during hierarchical cluster analysis with an agglomera-
tive approach and Ward's linkage.
FIGURE E1. (CONTINUED).
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CUT-OFFSTABLE E2. Describe biomarker groups demographics: age, sex, body mass index (BMI)










IgED EosD FeNOD IgED NoneD Total P value
Eos  150 mean (SD) 53 (15) 57 (14) 52 (15) 47 (18) 53 (15) 57 (15) 51 (15) 56 (16) 1,099 < .001
Eos  400 mean (SD) 54 (14) 56 (14) 53 (14) 51 (16) 50 (16) 58 (15) 51 (15) 55 (15) 1,099 < .001
FeNO  50 mean (SD) 54 (15) 58 (13) 52 (14) 51 (16) 52 (15) 54 (16) 50 (16) 56 (15) 1,099 < .001
IgE  30 mean (SD) 54 (14) 57 (15) 52 (14) 50 (16) 51 (15) 59 (16) 52 (16) 57 (14) 1,099 < .001
IgE  100 mean (SD) 53 (15) 57 (14) 51 (15) 48 (17) 52 (14) 57 (15) 51 (15) 55 (15) 1,099 < .001
IgE  300 mean (SD) 52 (15) 56 (14) 50 (16) 47 (17) 52 (14) 55 (15) 50 (16) 54 (15) 1,099 < .001
IgE  400 mean (SD) 52 (16) 56 (14) 50 (16) 46 (17) 52 (14) 55 (15) 49 (17) 54 (15) 1,099 < .001
IgE  700 mean (SD) 51 (16) 55 (14) 51 (16) 44 (16) 51 (14) 54 (16) 48 (18) 54 (15) 1,099 .002
Allergic sensitization
mean (SD)











IgED EosD FeNOD IgED NoneD Total P value
Eos  150
% (n)
58 (214) 69 (134) 59 (89) 60 (41) 70 (114) 69 (34) 64 (71) 75 (54) 1,175 .03
Eos  400
% (n)
58 (149) 67 (89) 53 (31) 60 (106) 63 (41) 69 (79) 64 (129) 75 (127) 1,175 .007
FeNO  50
% (n)
56 (116) 69 (64) 59 (121) 59 (38) 67 (109) 73 (22) 64 (140) 73 (141) 1,175 .008
IgE  30
% (n)
60 (241) 67 (50) 58 (73) 65 (95) 73 (46) 71 (37) 65 (145) 77 (64) 1,175 .03
IgE  100
% (n)
57 (165) 66 (126) 53 (41) 58 (57) 69 (78) 75 (75) 62 (94) 74 (115) 1,175 .001
IgE  300
% (n)
54 (88) 64 (203) 53 (19) 46 (26) 65 (100) 74 (106) 60 (50) 72 (159) 1,175 < .001
IgE  400
% (n)
52 (64) 64 (227) 55 (16) 47 (24) 64 (103) 73 (108) 60 (42) 71 (167) 1,175 .001
IgE 700
% (n)
49 (33) 63 (258) 50 (7) 57 (16) 64 (112) 68 (116) 59 (16) 69 (193) 1,175 .06
Allergic sensitization
% (n)











IgED EosD FeNOD IgED NoneD Total P value
Eos  150 mean (SD) 29 (6) 29 (7) 31 (9) 30 (8) 31 (7) 29 (7) 31 (9) 31 (8) 1,170 .007
Eos  400 mean (SD) 29 (6) 28 (6) 30 (8) 30 (7) 32 (8) 31 (7) 32 (9) 31 (8) 1,170 < .001
FeNO  50 mean (SD) 29 (6) 29 (7) 30 (8) 30 (7) 31 (7) 30 (7) 31 (9) 30 (7) 1,170 .03
IgE  30 mean (SD) 29 (7) 29 (7) 31 (8) 30 (7) 33 (8) 29 (7) 32 (9) 30 (7) 1,170 .001
IgE  100 mean (SD) 29 (7) 29 (7) 30 (9) 30 (7) 32 (8) 30 (6) 32 (9) 31 (8) 1,170 .003
IgE  300 mean (SD) 30 (7) 29 (7) 31 (9) 30 (8) 31 (8) 30 (6) 32 (10) 31 (8) 1,170 .001
IgE  400 mean (SD) 30 (7) 29 (7) 30 (8) 30 (8) 31 (8) 29 (6) 32 (9) 31 (8) 1,170 .003
IgE  700 mean (SD) 29 (7) 29 (7) 32 (8) 30 (9) 31 (8) 30 (6) 31 (10) 31 (8) 1,170 .006
Allergic sensitization
mean (SD)
30 (7) 28 (5) 29 (7) 30 (7) 30 (7) 30 (5) 31 (8) 35 (8) 808 < .001
Eos, blood eosinophils; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E.
TABLE E3. Asthma status: control, exacerbations, lung function










IgED EosD FeNOD IgED NoneD Total P value
Eos  150
% (n)
74 (153) 84 (95) 83 (69) 73 (30) 81 (70) 85 (23) 88 (45) 83 (25) 639 .2
Eos  400
% (n)
72 (107) 82 (61) 74 (23) 76 (76) 82 (32) 86 (57) 88 (91) 82 (63) 639 .07
FeNO  50
% (n)
74 (84) 88 (45) 73 (90) 75 (30) 79 (75) 86 (12) 87 (93) 84 (81) 639 .2
IgE  30
% (n)
76 (177) 81 (35) 74 (55) 75 (66) 84 (27) 92 (23) 89 (93) 85 (34) 639 .1
IgE  100
% (n)
75 (122) 80 (90) 76 (34) 74 (43) 79 (48) 84 (46) 92 (68) 84 (59) 639 .4
IgE  300
% (n)
76 (69) 77 (143) 67 (16) 76 (28) 81 (66) 80 (61) 98 (43) 84 (84) 639 .2
IgE  400
% (n)
76 (51) 77 (161) 70 (14) 76 (25) 79 (68) 80 (64) 97 (34) 85 (93) 639 .3
IgE  700
% (n)











IgED EosD FeNOD IgED NoneD Total P value
Eos  150 mean (SD) 4 (4) 4 (4) 4 (4) 4 (4) 4 (3) 4 (4) 4 (4) 4 (4) 541 >.99
Eos  400 mean (SD) 4 (4) 3 (3) 5 (5) 4 (3) 4 (4) 5 (5) 4 (4) 3 (3) 541 .4
FeNO  50 mean (SD) 4 (3) 5 (5) 5 (5) 4 (4) 4 (3) 6 (3) 4 (4) 4 (3) 541 .2
IgE  30 mean (SD) 4 (4) 3 (4) 5 (4) 4 (3) 4 (4) 6 (4) 4 (4) 4 (4) 541 .5
IgE  100 mean (SD) 4 (4) 4 (4) 5 (5) 4 (4) 4 (4) 4 (4) 4 (4) 4 (3) 541 .7
IgE  300 mean (SD) 4 (3) 4 (5) 4 (4) 5 (4) 5 (4) 4 (3) 4 (4) 3 (3) 541 .6
IgE  400 mean (SD) 4 (3) 4 (5) 3 (3) 5 (4) 5 (4) 4 (3) 4 (4) 4 (3) 541 .4
IgE  700 mean (SD) 4 (3) 4 (4) 4 (3) 6 (4) 5 (4) 4 (3) 4 (4) 4 (4) 541 .4











IgED EosD FeNOD IgED NoneD Total P value
Eos  150 mean (SD) 72 (22) 73 (21) 68 (23) 73 (23) 72 (21) 71 (18) 69 (18) 75 (22) 1,095 .3
Eos 400 mean (SD) 72 (22) 74 (20) 70 (30) 71 (22) 72 (21) 71 (20) 68 (20) 74 (22) 1,095 .2
FeNO  50 mean (SD) 72 (22) 74 (20) 69 (23) 71 (22) 72 (21) 63 (19) 71 (21) 74 (21) 1,095 .08
IgE  30 mean (SD) 72 (21) 76 (21) 69 (24) 72 (22) 70 (20) 70 (18) 72 (22) 72 (21) 1,095 .6
IgE  100 mean (SD) 72 (22) 73 (21) 68 (26) 72 (21) 70 (20) 71 (21) 69 (21) 74 (22) 1,095 .4
IgE  300 mean (SD) 71 (22) 73 (21) 69 (26) 73 (18) 69 (22) 71 (22) 72 (20) 72 (22) 1,095 .7
IgE  400 mean (SD) 71 (22) 73 (21) 66 (22) 73 (19) 70 (23) 71 (22) 72 (20) 72 (22) 1,095 .7
IgE  700 mean (SD) 68 (19) 73 (22) 64 (14) 72 (16) 69 (23) 71 (22) 75 (20) 71 (22) 1,095 .4
Allergic sensitization mean (SD) 74 (21) 80 (22) 75 (23) 73 (19) 75 (18) 74 (23) 73 (20) 70 (24) 744 .4
Eos, blood eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; IgE, immunoglobulin E.
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IgED EosD FeNOD IgED NoneD Total P value
Eos  150
% (n)
63 (150) 62 (77) 64 (68) 60 (21) 63 (76) 56 (19) 44 (40) 62 (37) 812 .4
Eos  400
% (n)
63 (112) 63 (52) 63 (24) 60 (59) 69 (35) 58 (44) 53 (84) 60 (78) 812 .5
FeNO  50
% (n)
64 (90) 53 (31) 61 (78) 63 (20) 68 (83) 70 (14) 54 (91) 58 (81) 812 .4
IgE  30
% (n)
62 (165) 62 (28) 64 (57) 63 (53) 64 (32) 55 (21) 55 (99) 55 (33) 812 .9
IgE  100
% (n)
64 (124) 58 (69) 64 (30) 65 (37) 64 (59) 57 (37) 50 (60) 61 (72) 812 .6
IgE  300
% (n)
65 (70) 60 (123) 52 (11) 61 (17) 66 (78) 61 (57) 55 (37) 55 (95) 812 .8
IgE  400
% (n)
62 (54) 62 (139) 53 (9) 59 (16) 66 (80) 61 (58) 56 (32) 55 (100) 812 .8
IgE  700
% (n)
65 (31) 61 (162) 67 (6) 57 (8) 64 (83) 61 (66) 63 (15) 54 (117) 639 .6
Allergic sensitization
% (n)











IgED EosD FeNOD IgED NoneD Total P value
Eos  150
% (n)
68 (112) 66 (61) 63 (35) 68 (17) 62 (50) 78 (18) 69 (38) 67 (23) 533 .6
Eos  400
% (n)
68 (85) 64 (41) 70 (16) 68 (44) 54 (20) 73 (38) 65 (57) 68 (53) 533 .4
FeNO  50
% (n)
66 (61) 61 (27) 67 (58) 76 (22) 63 (52) 100 (12) 66 (61) 66 (61) 533 .03
IgE  30
% (n)
65 (121) 63 (19) 62 (38) 73 (45) 69 (20) 82 (23) 65 (64) 65 (24) 533 .2
IgE  100
% (n)
69 (85) 59 (55) 59 (17) 71 (30) 67 (41) 79 (38) 65 (42) 65 (46) 533 .2
IgE  300
% (n)
70 (48) 62 (92) 50 (7) 76 (19) 67 (51) 75 (49) 74 (23) 62 (65) 533 .1
IgE  400
% (n)
68 (39) 63 (101) 55 (6) 75 (18) 66 (52) 76 (50) 77 (20) 62 (68) 533 .2
IgE  700
% (n)
68 (23) 64 (117) 75 (3) 73 (8) 64 (55) 76 (60) 73 (11) 64 (77) 533 .3
Allergic sensitization
% (n)











IgED EosD FeNOD IgED NoneD Total P value
Eos  150
% (n)
8 (26) 8 (14) 10 (14) 8 (5) 9 (13) 17 (8) 14 (15) 14 (9) 1069 .3
Eos  400
% (n)
8 (19) 7 (8) 10 (5) 7 (12) 9 (5) 13 (14) 13 (24) 11 (17) 1,069 0.7
FeNO  50
% (n)
7 (14) 7 (6) 9 (16) 5 (3) 10 (14) 11 (3) 13 (27) 12 (21) 1,069 .7
IgE  30
% (n)
8 (28) 8 (6) 12 (13) 10 (14) 5 (3) 10 (5) 13 (27) 11 (8) 1,069 .5
IgE  100
% (n)
7 (19) 9 (15) 12 (8) 11 (10) 8 (8) 10 (9) 13 (18) 12 (17) 1,069 .4
(continued)
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TABLE E5. Information about biologic medications
Biologic medications
Group Total Triple positive EosD FeNOD EosD IgED FeNOD IgED EosD FeNOD IgED Triple negative P value
Anti-IgE 194 37% (72) 7% (14) 14% (28) 13% (25) 2% (3) 2% (4) 21% (40) 4% (8) < .001
Anti-IL5 338 31% (104) 13% (45) 8% (26) 11% (37) 7% (25) 10% (32) 11% (38) 9% (31) .06
Biomarker before biologic 142 39% (55) 16% (22) 11% (16) 5% (7) 9% (13) 5% (7) 9% (12) 7% (10) .008












IgED EosD FeNOD IgED NoneD Total P value
IgE  300
% (n)
8 (12) 8 (22) 10 (3) 14 (7) 9 (13) 9 (12) 16 (13) 11 (22) 1,069 .3
IgE  400
% (n)
8 (9) 8 (25) 8 (2) 13 (6) 10 (14) 9 (13) 19 (13) 10 (22) 1,069 .2
IgE  700
% (n)
8 (5) 8 (29) 17 (2) 12 (3) 9 (14) 10 (16) 27 (7) 11 (28) 1,069 .07
Allergic sensitization
% (n)











IgED EosD FeNOD IgED NoneD Total P value
Eos  150
% (n)
41 (82) 38 (45) 32 (20) 29 (12) 33 (24) 29 (7) 23 (7) 26 (7) 577 .5
Eos  400
% (n)
43 (61) 37 (30) 33 (9) 33 (33) 46 (15) 36 (22) 27 (18) 24 (16) 577 .2
FeNO  50
% (n)
41 (47) 39 (22) 38 (41) 37 (15) 38 (33) 31 (5) 24 (18) 28 (23) 577 .1
IgE  30
% (n)
41 (95) 41 (19) 33 (21) 29 (25) 35 (8) 32 (7) 29 (20) 25 (9) 577 .4
IgE  100
% (n)
43 (67) 39 (47) 28 (10) 28 (16) 38 (19) 31 (16) 26 (11) 29 (18) 577 .1
IgE  300
% (n)
40 (34) 42 (80) 24 (5) 32 (12) 37 (24) 28 (20) 35 (8) 25 (21) 577 .2
IgE  400
% (n)
44 (26) 40 (88) 29 (5) 36 (12) 35 (24) 27 (20) 38 (8) 25 (21) 577 .2
IgE  700
% (n)
51 (18) 40 (96) 33 (2) 33 (7) 34 (27) 29 (25) 44 (4) 26 (25) 577 .2
Allergic sensitization
% (n)
34 (84) 32 (26) 31 (29) 14 (16) 18 (3) 29 (14) 15 (11) 23 (9) 717 < .001
Eos, blood eosinophils; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E.
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DENTON ETAL 2688.e7SECTION 3: BIOMARKER OVERLAP IN THOSE NOT
ON ORAL CORTICOSTEROIDS OR ANTI-
INTERLEUKIN-5FIGURE E2. Overlap of inflammatory biomarkers in those not on
oral corticosteroids or anti-interleukin-5 medications. FeNO, frac-
tional exhaled nitric oxide; IgE, immunoglobulin E.
